Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
80.69 USD | -0.20% | +7.49% | -16.31% |
Kurzporträt
Mitarbeiterzahl: 3 401
Umsatz nach Geschäftsbereich
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Innovative Therapies
100,0
%
| 2 096 | 100,0 % | 2 419 | 100,0 % | +15.42% |
Umsatz je Region
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
31,9
%
| 684 | 32,6 % | 771 | 31,9 % | +12.72% |
Europe
27,7
%
| 651 | 31,1 % | 669 | 27,7 % | +2.82% |
Rest of World
19,4
%
| 312 | 14,9 % | 468 | 19,4 % | +50.28% |
Latin America
13,7
%
| 267 | 12,7 % | 332 | 13,7 % | +24.60% |
Global
7,4
%
| 182 | 8,7 % | 178 | 7,4 % | -2.47% |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Alexander Hardy
CEO | Chief Executive Officer | 56 | 01.12. |
Brian Mueller
DFI | Director of Finance/CFO | 50 | 01.12.02 |
C. Guyer
CTO | Chief Tech/Sci/R&D Officer | 62 | 01.05.20 |
Henry Fuchs
CTO | Chief Tech/Sci/R&D Officer | 66 | 01.03.09 |
Philip Lo Scalzo
CMP | Compliance Officer | - | 01.01.07 |
Chief Tech/Sci/R&D Officer | - | 01.11.08 | |
Stuart Bunting
CTO | Chief Tech/Sci/R&D Officer | - | 01.11.08 |
Kevin Eggan
CTO | Chief Tech/Sci/R&D Officer | - | 05.10.20 |
Traci McCarty
IRC | Investor Relations Contact | - | - |
Ganesh Vedantham
PRN | Corporate Officer/Principal | - | 04.10.21 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 04.01.16 |
Randy Meier
CHM | Chairman | 65 | 14.12.06 |
Elaine Heron
BRD | Director/Board Member | 76 | 01.07.02 |
May Kin Ho
BRD | Director/Board Member | 71 | 17.02.21 |
Mark Enyedy
BRD | Director/Board Member | 60 | 27.12. |
Robert Hombach
BRD | Director/Board Member | 58 | 29.09.17 |
Director/Board Member | 52 | 27.12. | |
Willard Dere
BRD | Director/Board Member | 70 | 18.07.16 |
Director/Board Member | 66 | 10.07.19 | |
Barbara Bodem
BRD | Director/Board Member | 56 | 27.12. |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 189 879 803 | 188 223 673 ( 99,13 %) | 0 | 99,13 % |
Unternehmenskontakt
BioMarin Pharmaceutical, Inc.
770 Lindaro Street
94901, San Rafael
+415 506 6700
http://www.biomarin.comKonzerngesellschaften
Name | Kategorie und Branche |
---|---|
BioMarin International Ltd.
BioMarin International Ltd. BiotechnologyHealth Technology BioMarin International develops and commercializes biopharmaceuticals. The company was founded on June 16, 2011 and is headquartered in Dublin, Ireland. |
Biotechnology
|
Sektor
Umsatz je Region
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
-16.31% | 15.32 Mrd. | |
+0.82% | 91.94 Mrd. | |
-1.32% | 38.74 Mrd. | |
+64.20% | 26.66 Mrd. | |
-5.78% | 13.3 Mrd. | |
-11.38% | 11.65 Mrd. | |
+173.10% | 10.37 Mrd. | |
-49.84% | 10.12 Mrd. | |
+4.27% | 9.06 Mrd. | |
-16.26% | 7.46 Mrd. |
- Börse
- Aktien
- 924801 Aktie
- Unternehmen BioMarin Pharmaceutical Inc.